Providing a wealth of insights drawn from the experience of groundbreaking researchers working in the field, this Second Edition of a landmark volume brings preclinical and clinical studies of Filgrastim (r-metHuG-CSF) up to date with completely revised and expanded discussions of its biology, biochemistry, structure, pharmacology, clinical applications, and pharmacoeconomics. Explores how Filgrastim reduces infectious complications in the management of cancer, AIDS, severe chronic neutropenia, neutropenia associated with ...
Read More
Providing a wealth of insights drawn from the experience of groundbreaking researchers working in the field, this Second Edition of a landmark volume brings preclinical and clinical studies of Filgrastim (r-metHuG-CSF) up to date with completely revised and expanded discussions of its biology, biochemistry, structure, pharmacology, clinical applications, and pharmacoeconomics. Explores how Filgrastim reduces infectious complications in the management of cancer, AIDS, severe chronic neutropenia, neutropenia associated with nonmalignant autoimmune diseases, non-neutropenic infections, lymphoma, leukemia, diabetic foot infection, and more! Now enhanced with 13 new chapters, Filgrastim (r-metHuG-CSF) in Clinical Practice, Second Edition features novel research as well as provocative and enhanced information on pharmacokinetic-pharmacodynamic modeling to delineate concentration-response relationships Filgrastim as treatment or prophylaxis for decreasing infectious episodes, intensifying immunosuppresive therapy, and mobilizing progenitor stem cells improving granulocyte collection yields from normal donors and neutrophil transfusions in recipients of such products the potential of peripheral blood progenitor cell (PBPC) transplantation in diseases, such as rheumatoid arthritis maintaining optimal chemotherapy intensity in situations where dose reduction or delay is necessary combining Filgrastim with various cytokines, including granulocyte-macrophage colony-stimulating factor, stem-cell factor, rHuSCF, IL-3, and erythropoietin Filgrastim's toxicity profile, daily aspects of administration, economic impact, and effect on patients' quality of life and much more! Containing over 1650 references-more than 600 new to this edition!-this truly outstanding Second Edition continues to furnish unparalleled coverage of the subject matter for oncologists, hematologists, infectious disease specialists, immunologists, radiotherapists, oncological nurses, and graduate and medical school students in these disciplines.
Read Less
Add this copy of Filgrastim (R-Methug-Csf) in Clinical Practice, Second to cart. $45.00, good condition, Sold by J. Hood, Booksellers, Inc. rated 5.0 out of 5 stars, ships from Baldwin City, KS, UNITED STATES, published 1998 by Marcel Dikker, Inc.
Add this copy of Filgrastim (R-Methug-Csf) in Clinical Practice. 2nd to cart. $50.96, like new condition, Sold by Rob the Book Man rated 4.0 out of 5 stars, ships from Vancouver, WA, UNITED STATES, published 1998 by Monticello, New York, U.S.A. : Marcel Dekker Inc, 1998.
Add this copy of Filgrastim (R-Methug-Csf) in Clinical Practice to cart. $94.13, new condition, Sold by discount_scientific_books rated 5.0 out of 5 stars, ships from Sterling Heights, MI, UNITED STATES, published 1998 by CRC Press.
Add this copy of Filgrastim (R-Methug-Csf) in Clinical Practice, Second to cart. $118.35, new condition, Sold by discount_scientific_books rated 5.0 out of 5 stars, ships from Sterling Heights, MI, UNITED STATES, published 1998 by CRC Press.
Add this copy of Filgrastim in Clinical Practice to cart. $119.60, new condition, Sold by Media Smart rated 3.0 out of 5 stars, ships from Hawthorne, CA, UNITED STATES, published 1998 by Taylor & Francis Group.
Add this copy of Filgrastim(R-Methug-Csf) in Clinical Practice, 2/Ed to cart. $135.59, new condition, Sold by Books International rated 4.0 out of 5 stars, ships from Toronto, ON, CANADA, published 1998 by CRC Press.
